BioSig Technologies Retains Donohoe Advisory Associates LLC

LOS ANGELES, CA--(Marketwired - April 10, 2015) - BioSig Technologies (OTCQB: BSGM) today announced that it has retained Donohoe Advisory Associates LLC of Rockville, Maryland to advise and assist the Company in its efforts to obtain a listing on a national securities exchange.

Donohoe Advisory, founded by David A Donohoe, Jr. in 2004, has successfully represented dozens of companies seeking to list on U.S. stock exchanges. Prior to forming Donohoe Advisory, Mr. Donohoe spent nine years with The NASDAQ Stock Market where he ultimately served as Chief Counsel in the Listings Qualifications Department. Bruce Poignant, who serves as a Senior Consultant for Donohoe Advisory, will also be working closely with the team. Mr. Poignant spent more than 20 years in the Exchange space, working at both the American Stock Exchange and the NYSE. Over the past 10 years, he was a member of capital markets groups at both the AMEX and NYSE working with numerous companies to help them navigate through the listing process. Additional information relating to Donohoe Advisory is available at www.donohoeadvisory.com.

Kenneth L. Londoner, co-Founder and Executive Chairman of BioSig, stated, "We are pleased to be working with Donohoe Advisory and look forward to their advice and counsel on seeking a national listing for our Company."

About BioSig Technologies
BioSig Technologies is a medical device company that has developed a proprietary technology platform designed to greatly improve the $3 billion electrophysiology (EP) marketplace(1) (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP System.

PURE EP System is a next-generation surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing guidance in identifying ablation targets -- areas of tissue to destroy that otherwise create a heart rhythm disturbance (arrhythmia).

Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 2019(1) -- making it one of the fastest growing medical device segments. Just in the U.S., the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017(2).

BioSig intends to seek FDA 510(k) approval for the PURE EP System. The Company has already achieved proof of concept validation through UCLA EP & Animal Labs, and is collaborating with several of the nation's most prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UCLA Cardiac Arrhythmia Center, and Mayo Clinic.

(1) Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

(2) HRI 2013 "Global Opportunities in Medical Devices & Diagnostics" report; triangulation of multiple sources; *AF includes left atrial tachycardia, left WPW, left atrial flutter.